Atagabalin

Atagabalin
Clinical data
Other names	PD-0200390; PD-200390; PD0200390; PD200390
Routes of; administration	Oral
ATC code	none;
Identifiers
	IUPAC name [(3S,4S)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid;
CAS Number	223445-75-8 ;
PubChem CID	9794485;
ChemSpider	7970252 ;
UNII	JT7957Q2FB;
ChEMBL	ChEMBL593430 ;
CompTox Dashboard (EPA)	DTXSID80944993 ;
Chemical and physical data
Formula	C10H19NO2
Molar mass	185.267 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H]1CC(C[C@@H]1C)(CC(=O)O)CN;
	InChI InChI=1S/C10H19NO2/c1-7-3-10(6-11,4-8(7)2)5-9(12)13/h7-8H,3-6,11H2,1-2H3,(H,12,13)/t7-,8-/m0/s1 ; Key:IUVMAUQEZFTTFB-YUMQZZPRSA-N ;
	(what is this?) (verify)

Atagabalin (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name PD-0200390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α₂δ calcium channels (1 and 2).^[1]^[2] It was under development as a treatment for insomnia, but was discontinued following unsatisfactory trial results.^[1]^[3]^[4]^[5]^[6] The drug reached phase 2 clinical trials for this indication prior to the discontinuation of its development.^[1]

References

^ ^a ^b ^c ^d "Atagabalin". AdisInsight. 5 November 2023. Retrieved 3 October 2025.
^ Blakemore DC, Bryans JS, Carnell P, Carr CL, Chessum NE, Field MJ, Kinsella N, Osborne SA, Warren AN, Williams SC (January 2010). "Synthesis and in vivo evaluation of bicyclic gababutins". Bioorganic & Medicinal Chemistry Letters. 20 (2): 461–4. doi:10.1016/j.bmcl.2009.11.118. PMID 20005103.
^ Atkin T, Comai S, Gobbi G (April 2018). "Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery". Pharmacol Rev. 70 (2): 197–245. doi:10.1124/pr.117.014381. PMID 29487083.
^ Corrigan B, Feltner DE, Ouellet D, Werth JL, Moton AE, Gibson G (August 2009). "Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit". British Journal of Clinical Pharmacology. 68 (2): 174–80. doi:10.1111/j.1365-2125.2009.03444.x. PMC 2767279. PMID 19694735.
^ Quintero JE, Pomerleau F, Huettl P, Johnson KW, Offord J, Gerhardt GA (May 2011). "Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: Basic characterization and drug pharmacology". Brain Research. 1401: 1–9. doi:10.1016/j.brainres.2011.05.025. PMC 3197737. PMID 21664606.
^ Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO (June 2011). "Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models". Pharmaceutical Research. 28 (10): 2610–27. doi:10.1007/s11095-011-0490-x. PMID 21681607. S2CID 22241527.

This sedative-related article is a stub. You can help Wikipedia by expanding it.

[AdisInsight-1] "Atagabalin". AdisInsight. 5 November 2023. Retrieved 3 October 2025.

[pmid20005103-2] Blakemore DC, Bryans JS, Carnell P, Carr CL, Chessum NE, Field MJ, Kinsella N, Osborne SA, Warren AN, Williams SC (January 2010). "Synthesis and in vivo evaluation of bicyclic gababutins". Bioorganic & Medicinal Chemistry Letters. 20 (2): 461–4. doi:10.1016/j.bmcl.2009.11.118. PMID 20005103.

[AtkinComaiGobbi2018-3] Atkin T, Comai S, Gobbi G (April 2018). "Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery". Pharmacol Rev. 70 (2): 197–245. doi:10.1124/pr.117.014381. PMID 29487083.

[pmid19694735-4] Corrigan B, Feltner DE, Ouellet D, Werth JL, Moton AE, Gibson G (August 2009). "Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit". British Journal of Clinical Pharmacology. 68 (2): 174–80. doi:10.1111/j.1365-2125.2009.03444.x. PMC 2767279. PMID 19694735.

[pmid21664606-5] Quintero JE, Pomerleau F, Huettl P, Johnson KW, Offord J, Gerhardt GA (May 2011). "Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: Basic characterization and drug pharmacology". Brain Research. 1401: 1–9. doi:10.1016/j.brainres.2011.05.025. PMC 3197737. PMID 21664606.

[pmid21681607-6] Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO (June 2011). "Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models". Pharmaceutical Research. 28 (10): 2610–27. doi:10.1007/s11095-011-0490-x. PMID 21681607. S2CID 22241527.

[1]

[2]

[3]

[4]

[5]

[6]

See also

References